- Home
- CSQ vs CPRX Comparison
CSQ vs CPRX Comparison
Compare CSQ & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSQ
- CPRX
- Stock Information
- Founded
- CSQ 2003
- CPRX 2002
- Country
- CSQ United States
- CPRX United States
- Employees
- CSQ N/A
- CPRX N/A
- Industry
- CSQ Finance Companies
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- CSQ Finance
- CPRX Health Care
- Exchange
- CSQ Nasdaq
- CPRX Nasdaq
- Market Cap
- CSQ 2.8B
- CPRX 2.6B
- IPO Year
- CSQ N/A
- CPRX 2006
- Fundamental
- Price
- CSQ $18.02
- CPRX $21.12
- Analyst Decision
- CSQ
- CPRX Strong Buy
- Analyst Count
- CSQ 0
- CPRX 6
- Target Price
- CSQ N/A
- CPRX $32.83
- AVG Volume (30 Days)
- CSQ 220.3K
- CPRX 1.3M
- Earning Date
- CSQ 01-01-0001
- CPRX 08-06-2025
- Dividend Yield
- CSQ 7.53%
- CPRX N/A
- EPS Growth
- CSQ N/A
- CPRX 178.13
- EPS
- CSQ N/A
- CPRX 1.57
- Revenue
- CSQ N/A
- CPRX $534,645,999.00
- Revenue This Year
- CSQ N/A
- CPRX $16.37
- Revenue Next Year
- CSQ N/A
- CPRX $8.80
- P/E Ratio
- CSQ N/A
- CPRX $13.47
- Revenue Growth
- CSQ N/A
- CPRX 29.97
- 52 Week Low
- CSQ $12.50
- CPRX $15.34
- 52 Week High
- CSQ $16.45
- CPRX $26.58
- Technical
- Relative Strength Index (RSI)
- CSQ 43.41
- CPRX 43.70
- Support Level
- CSQ $18.25
- CPRX $20.76
- Resistance Level
- CSQ $18.56
- CPRX $21.71
- Average True Range (ATR)
- CSQ 0.21
- CPRX 0.59
- MACD
- CSQ -0.06
- CPRX 0.10
- Stochastic Oscillator
- CSQ 11.76
- CPRX 44.07
About CSQ Calamos Strategic Total Return
Calamos Strategic Total Return Fund is a diversified, closed-end management investment company. The fund's objective is to provide total return through a combination of capital appreciation and current income. Its investment portfolio comprises equities, convertible securities, and high-yield corporate bonds.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).